Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03226431 · ClinicalTrials.gov registry record · Phase 1
Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0
A Phase 1 study of Lung Transplant, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT03226431 is a Phase 1 study of Lung Transplant that has completed, run by Duke University. The registered enrollment target is 6 participants, below the 1,276-participant average among 15 other Lung Transplant trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03226431, a Phase 1 study of Lung Transplant, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
To treat an intermediate size patient population of bilateral lung transplant patients with CLAD-0.
Conditions Studied
Interventions
- DRUG Ascorbic Acid
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-12-11 |
| Est. Completion | 2019-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03226431
The ClinicalTrials.gov registry entry for NCT03226431 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,276-participant average among 15 other Lung Transplant trials with a reported enrollment target (100% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Transplant appearing as the primary indexed condition, and to 1 intervention - of which Ascorbic Acid is the first listed.
NCT03226431 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03226431 about?
NCT03226431 is a clinical study titled "Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0". To treat an intermediate size patient population of bilateral lung transplant patients with CLAD-0.
What is the current status of trial NCT03226431?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2017-12-11. Estimated completion is 2019-06-25.
What conditions does trial NCT03226431 study?
This clinical trial studies the following conditions: Lung Transplant.
What interventions are being tested in trial NCT03226431?
The interventions under investigation include: Ascorbic Acid (DRUG).
Who is sponsoring clinical trial NCT03226431?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03226431 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Transplant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension
RECRUITING · Phase 1
-
DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
RECRUITING
-
Pre-transplant Health Coaching to Improve Patient-Reported Outcomes in Lung Transplant Candidates
RECRUITING · NA
-
Planned Semi-Elective Lung Tx Study
RECRUITING · NA
-
Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant Recipients
RECRUITING · Phase 2
-
Tocilizumab in Lung Transplantation
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.